Seid launches Menocta® and Seidivid® FERTY 4 at Ginep 2021.

SEID LAB has chosen the setting for the next Ginep 2021 Scientific Meeting (of Private Gynecology), which will be held in Toledo on June 11 and 12, to officially present its two new developments Menocta® and Seidivid® FERTY 4.

Fulfilling its objective of providing the gynecologist with new tools to improve the health and well-being of women, SEID has developed Seidivid® FERTY4, which comes to update its range of Seidivid® products (Seidivid® and Seidivid® Plus) with a new multi-action preconceptive formula, unique in its category and reinforced in four essential axes to specifically contribute to increasing the chances of pregnancy for women with gestational desire.

Those four essential axes covered by the new Seidivid® FERTY4 formula are:

Oocyte maturation (by combining Mio and d-Chiro-inositores 40: 1, CoQ10, Melatonin and 1,000IU of vitamin D3)
Control of the risk factor for thrombophilias / hyperhomocysteinemia (by combining Quatrefolic® and vitamins B6 and B12)
Control of endometrial dysbiosis risk factor (using lactobacillus 3×109)
Preparation for pregnancy (thanks to Quatrefolic®, iodine, iron and zinc).

The second novelty that SEID will officially present at Ginep is Menocta® , a new tool – non-hormonal, non-phytoestrogenic and non-uterotropic – in the hands of the gynecologist for the management of vegetative symptoms (sweating and hot flashes) and neuropsychological (sleep, mood and libido alterations) of women in menopause or in transition to menopause.

Menocta® conjugates the serotonergic effect of cytoplasmic pollen extract (10% amino acids), of the Black cohosh and 5-Hydroxytryptophan and melatonin (1.9 mg), to achieve an increase in quality of life and sleep quality during climacteric, without any interaction with estrogen receptors in the breast or in the endometrium.

More information about Ginep 2021 at https://www.ginep.es/ .